Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Dr. Scott Pollack – IDO Inhibitors and their Pharmacological Effects

In conjunction with his presentation at the London Excel at ELRIG Drug Discovery 2018, Dr. Scott Pollack, Associate Director of Biophysics and Enzymology at Sygnature Discovery, was asked:

“What are IDO inhibitors and how do you assess their pharmacological effects?”

Latest News

View All

Sygnature Discovery and Daewoong Pharma announce research…

New platform set to accelerate early-stage targeted…

Sygnature Discovery completes acquisition of SB Drug…

Sygnature Discovery partners the Oncology Development Programme…